BREAKING
Why Is PLTR Stock Up Today? Technical Rebound Follows Brutal February Selloff 29 minutes ago Palantir Technologies Inc. (PLTR) Surges 5.0% — Developing Story 29 minutes ago Live Nation Entertainment, inc (LYV) Misses Q4 2025 Earnings Estimates — EPS $0.73 vs $1.49 Expected 37 minutes ago GRAIL, Inc (GRAL) Tops Q4 2025 Earnings Estimates — EPS $-2.46 vs $-3.26 Expected 38 minutes ago Sensata (ST) Beats Q4 EPS Estimates By 4.6% In Third Consecutive Quarter 38 minutes ago Sensata Technologies Holding plc (ST) Tops Q4 2025 Earnings Estimates — EPS $0.89 vs $0.85 Expected 38 minutes ago Vicor (VICR) Q4 EPS of $0.63 Crushes Estimates by 425%, Revenue Surges 27.8% 39 minutes ago Vicor Corporation (VICR) Tops Q4 2025 Earnings Estimates — EPS $0.63 vs $0.12 Expected 39 minutes ago Why RingCentral Stock Dropped Despite Beating Earnings Estimates by 5.2% 40 minutes ago RingCentral, Inc (RNG) Tops Q4 2025 Earnings Estimates — EPS $1.13 vs $1.07 Expected 40 minutes ago Why Is PLTR Stock Up Today? Technical Rebound Follows Brutal February Selloff 29 minutes ago Palantir Technologies Inc. (PLTR) Surges 5.0% — Developing Story 29 minutes ago Live Nation Entertainment, inc (LYV) Misses Q4 2025 Earnings Estimates — EPS $0.73 vs $1.49 Expected 37 minutes ago GRAIL, Inc (GRAL) Tops Q4 2025 Earnings Estimates — EPS $-2.46 vs $-3.26 Expected 38 minutes ago Sensata (ST) Beats Q4 EPS Estimates By 4.6% In Third Consecutive Quarter 38 minutes ago Sensata Technologies Holding plc (ST) Tops Q4 2025 Earnings Estimates — EPS $0.89 vs $0.85 Expected 38 minutes ago Vicor (VICR) Q4 EPS of $0.63 Crushes Estimates by 425%, Revenue Surges 27.8% 39 minutes ago Vicor Corporation (VICR) Tops Q4 2025 Earnings Estimates — EPS $0.63 vs $0.12 Expected 39 minutes ago Why RingCentral Stock Dropped Despite Beating Earnings Estimates by 5.2% 40 minutes ago RingCentral, Inc (RNG) Tops Q4 2025 Earnings Estimates — EPS $1.13 vs $1.07 Expected 40 minutes ago
JNJ

Johnson & Johnson

$JNJ NYSE Feb 18, 2026 All Day FY 2026

Investor Toolbox

Listen to Call

Recording not yet available.

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer Feb 18, 2026 Event Johnson & Johnson (JNJ) FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month Feb 17, 2026 Event Johnson & Johnson (JNJ) Sec Form 10K Feb 12, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025 Jan 21, 2026 Research Johnson & Johnson: Healthcare Outlook Jan 20, 2026